



# 10 Years of Proton Radiotherapy of Ocular Melanoma at IFJ PAN

*10 lat radioterapii protonowej oka w IFJ PAN*

Tomasz Kajdrowicz



Cyclotron Center Bronowice, Institute of Nuclear Physics PAN, Kraków, Poland

- Construction of ocular treatment rooms
- Proton eye treatment procedure
- Treatment planning and patient positioning verification
- Solving stroboscopic effect in depth dose distribution
- Research and Development
- Acknowledgements


**$10^{-6}$  to  $10^{-5}$  seconds after The Big Bang ...**

... quarks started formation of Baryons like protons.



- Proton is forming nucleus of hydrogen
- Hydrogen is the most common chemical element in the universe
- Each proton consists of two up quarks and one down quark
- As a consequence it has a **positive electric charge** ...
- ... and as such it can be **accelerated by electric field**
- Accelerated protons slow down in matter losing energy mostly due to **multiple electromagnetic collisions** with atomic electrons and nuclei
- Atomic electrons gain energy leading to **ionization of atoms**
- Proton is **1840 times heavier than electron**
- It travels through tissue like matter on average in **straight lines**




Single







Double





- Minimum dose to kill all tumor cells
- Limit of normal tissue complications
- Main organs at risk (OAR) of an eye
  - Optic disc and nerve
  - Macula
  - Ciliary body and lens



- Iris melanoma
- Conjunctival melanoma
- Malignant melanoma
- Retinoblastoma
- Melanocytoma
- **Choroidal melanoma**



# Why protons?



William Henry Bragg  
(1862 – 1942)

# Centrum Radioterapii Protonowej przy IFJ w Krakowie

15<sup>th</sup> December, 1994

**Prof. dr hab. Andrzej Budzanowski** submits a project proposal to „Fundacja Współpracy Polsko-Niemieckiej” (*Stiftung für deutsch-polnische Zusammenarbeit*)

Partners on German side are:

- Institut fuer Medicin Forschungszentrum Juelich
- Hahn Meitner Institut, Berlin



**III. WNIOSK O DOTACJE**

1. Tytuł projektu:  
Centrum Radioterapii Hadronowej przy IFJ w Krakowie

2. Walekowany o dotację w kwocie 4.994.000,- zł

a. słownie cztery miliony dziewięćset dziewięćdziesiąt cztery tysiące zł  
b. równowartość w DM: 3.212 miliona marek

3. Wnioskodawca

a. polski niemiecki (podkreślij właściwe)  
b. nazwa wnioskodawcy:  
Prof. dr hab. Andrzej Budzanowski  
Dyrektor  
Instytut Fizyki Jądrowej  
im. Henryka Niewodniczańskiego  
w Krakowie

c. składający adres i telefon:  
Instytut Fizyki Jądrowej im. H. Niewodniczańskiego  
PL 31-342 Kraków  
tel. (48 12) 370222  
fax (48 12) 375441

d. forma prawa:  
Zgodnie z załączonymi ogólnymi Statutu IFJ zatwierdzonym w dniu 7 kwietnia 1992 przez Prezesa Państwowej Agencji Atomistyki:  
Art. 1. Instytut Fizyki Jądrowej imienia Henryka Niewodniczańskiego działa na podstawie ustawy o instytucjach badawczo-rozwojowych  
1) Ustawy z dnia 25 lipca 1985 o jednostkach badawczo-rozwojowych (tekst jednolity Dz. U. z. 1991 i Nr. 44, poz. 194),  
2) uchwałą Rady Ministrów z dnia 20 lipca 1980 w sprawie utworzenia Instytutu Fizyki Jądrowej w Krakowie,  
3) statutu, zatwierdzonego j.w.

Art. 2.1. Instytut Fizyki Jądrowej posiada osobowość prawną.  
2. Siedziba Instytutu Fizyki Jądrowej Kraków  
4. Nadszur Instytutem sprawuje Prezes Państwowej Agencji Atomistyki.

Tabela 1. Ogólny harmonogram realizacji projektu

Nazwa zadania	1995	1996	1997	1998
T-1 Zaistalowanie cyklotronu AIC-144 w hali eksplotacyjnej				
T-2 Adaptacja Cyklotronu AIC-144 dla potrzeb terapii protonowej				
T-3 Sterowanie i automatyzacja pracy AIC-144 w systemie komputerowym				
T-4 Opracowanie i wykonanie traktów transportu i formowania wiązek terapeutycznych				
T-5 Wyposażenie stanowisk radioterapii neutronowej oraz terapii protonowej oka				
K-1. Opracowanie metod i ocena skuteczności radioterapii neutronowej mięsaków				
K-2 Opracowanie metod leczenia i ocena skuteczności radioterapii neutronowej mięsaków				
K-3 Próby kliniczne terapii protonowej u chorych z czerniakiem oka				
K-4. Monitorowanie aktywności makrotagów metodą ERP od pacjentów leczonych neutronami				
Z-1 Opracowanie nowego modelu zwierzęcych czerników oka u chomików i gerbili				
Z-2 Testowanie zestawu do terapii protonowej na zwierzęcych modelach czerniaka oka				
Z-3 Analiza możliwości wykorzystania spektroskopii ERP dla celów prognostycznych w leczeniu				
Z-4 Porównanie RBE w indukowaniu różnych efektów biologicznych przy użyciu wiązki neutronowej				
Z-5 Opracowanie biologicznej dozymetrii dawki pochłoniętej w limfocytach krwi ludzkiej				
Z-6 Wczesny i późny odczyn popromienny tkanki zdrowej po napromienianiu neutronami i protonami				
Z-7 Obliczenia transportu i depozycji energii promieniowania w nawiązaniu dla adaptacji cyklotronu AIC-144				
Z-8 Przygotowanie kadry fizyków medycznych dla celów radioterapii hadronowej				
Z-9 Mikrodozymetryczna ocena jakości biologicznej wiązki neutronów i protonów				
R-1 Produkcja radioizotopów medycznych				

# Summer 2-week-long Internship at IFJ PAN

Summer, 1997


2-week-long internship organized by dr Paweł Olko  
to write a prototype of a treatment planning system (TPS)  
for proton therapy of ocular melanoma

Spring, 2000

TPS functional prototype as a part of Master Thesis


Autumn, 2005

FDA approved and CE marked commercial TPS  
(2 free-of-charge licenses for IFJ PAN)



Akademia Górnictwo – Hutnicza  
im. Stanisława Staszica w Krakowie

Wydział Fizyki i Techniki Jądrowej



Praca magisterska

Mateusz Bajer, Tomasz Kajdrowicz  
kierunek fizyka techniczna  
specjalność fizyka komputerowa

Eyeplan  
Komputerowe planowanie i wspomaganie  
protonowej terapii nowotworów oka

Opiekun dr Mariusz Kopeć

Kraków 2000

## Starting cooperation with Clinical Partners

First cooperation agreement between Collegium Medicum UJ  
- Krakow University Hospital and IFJ PAN  
on development of proton eye therapy signed on 27.06.2005

Funding elements of the treatment room from the National Fund for Fighting Cancer (University Hospital) – 2006

Public tenders and installation  
of equipment at IFJ PAN – 2007-2008




# Proton beam range sufficient to treat ocular patients


19<sup>th</sup> December, 2005

Working Meeting at Kopernika Street in Kraków

- prof. Bożena Romanowska-Dixon
- prof. Paweł Olko
- dr Jan Swakon
- Tomasz Kajdrowicz



AIC-144 cyclotron produces 60 MeV protons resulting in range in water of 29 mm.



Discussing patient proton beam range requirements for sample Polish population.

Mean eye length with sclera is 24.6 mm.

**More than 95% cases could be treated with 60 MeV proton beam from AIC-144 cyclotron.**



## AIC-144:

- Weight 150 tons
- **60 MeV – 29 mm H<sub>2</sub>O**
- Up to 100 nA
- **Pulsed beam at 50 Hz**

AIC-144




Proteus C-235




## Proteus C-235:


- Weight 220 tons
- **70 – 230 MeV 4 – 32 cm H<sub>2</sub>O**
- Up to 600 nA
- **Quasi-continuous beam at 106 MHz**

## Ocular treatment room at AIC-144 cyclotron



(Swakoń J., Sulikowski J., Olko P., technical departments and many others)







Declaration of Conformity  
Proteus 235

This IAEA-1293 Proteus 235 installed in:

The Henryk Niewodniczanski - Institute of Nuclear Physics - Polish Academy of Sciences  
ul. Radzikowskiego 152,  
31-342 Krakow, Poland

is a specific configuration of the Proteus 235 product as described through the Therapy System Delivery note  
(ID 15596 and ID 2164) and is summarized in Annex A of this declaration.

We hereby declare that the above mentioned device as described through the Therapy System Delivery note  
(ID 15596 and ID 2164) is a class II device and complies with the applicable requirements of the European  
Council Directive 93/42/EEC as amended by Directive 98/9/EC, Directive 2006/73/EC, Directive  
2007/40/EC, Regulation (EC) No 1832/2005, Directive 2007/41/EC.  
This declaration of conformity is done according to Annex II, excluding paragraph 4, of the above mentioned  
directive.

The IBA Proton Therapy System, Proteus 235, is a medical device designed to produce and deliver a proton  
beam for the treatment of patients with localized cancers and other conditions susceptible to treatment by  
radiation. The PTS may include a fixed small beam treatment room dedicated to the treatment of patients with  
localized tumors and other conditions susceptible to treatment by radiation localized to the head and neck.

The product has been manufactured under an ISO 13485:2003 quality management system approved by  
LRQA, approval number LHQ 9969876.

Lorraine Le Picard,  
15.03.2016



Anne-Sophie Groll, PhD  
Group Regulatory Affairs Director  
IBA Group


EcC-NID-40084 ©

Tempam Ref. M-04-012

112



- ❑ Developed at IFJ PAN
  - ❑ 70 MeV at nozzle entrance
  - ❑ CE marking in collaboration with IBA
  - ❑ Treating patients since 2016
- (Swakoń J., Horwacik T., Góra Ł. and many others)*



## Advantages of the new eye treatment room

- bigger maximum beam range allowing for all treatment cases
- excellent beam stability
- robotic chair with isocentric rotation
- automatic digital imaging
- faster workflow
- patient waiting rooms

## Who helped us?

- Hahn Meitner Institut (Helmholtz-Zentrum), Berlin, Germany
- Clatterbridge Cyclotron Centre, Liverpool, UK
- Centre de Protonthérapie (Curie Institut), Orsay, France
- Laboratori Nazionali del Sud, Catania, Italy
- Paul Scherrer Institute, Villingen, Switzerland
- University of Florida Health Proton Therapy Institute, Jacksonville, USA



Andreas Weber


## Whom we helped?

- Fondazione Centro Nazionale Adroterapia Oncologica, Pavia, Italy
- National Cancer Center, Seoul, Korea
- Holland PTC, Delft, Nederlands

## Patient preparation – tantalum markers surgery



prof. M. H. Foerster  
(Charité, Berlin)




prof. B. Romanowska-Dixon  
(CM UJ, Kraków)



Szpital  
Uniwersytecki  
w Krakowie

## Clinical data needed for treatment planning:


- Intraoperative measurements
- Ultrasound
- IOL Master
- Optical Coherent Tomography
- Fundus images
- MRI / CT




Centrum Onkologii  
Instytut im. Marii Skłodowskiej-Curie  
Oddział w Krakowie





Szpital  
Uniwersytecki  
w Krakowie



## Patient immobilization – thermoplastic mask and bite block




# Proton eye treatment procedure – patient positioning



# Treatment simulations

- To fit eye ball to markers
- To check patient ability to follow fixation lights



**Simulation comparison**

General					
	Series #1	Series #2	Series #3	Series #4	Series #5
Polar					Clinical
Azimuthal	0.00 deg	130.00 deg	40.00 deg	210.00 deg	180.00 deg
Eye length	24.70 mm	24.70 mm	24.70 mm	24.70 mm	24.70 mm
Chi-square	0.00	0.05	0.06	0.01	0.13
Eye center	X -5.00 mm	-5.70 mm	-4.53 mm	-5.53 mm	-5.70 mm
	Y -1.93 mm	-1.57 mm	-2.41 mm	-2.20 mm	-2.04 mm
	Z -1.88 mm	-2.44 mm	-1.65 mm	-2.89 mm	-3.07 mm





Clips errors					
	Series #1	Series #2	Series #3	Series #4	Series #5
Clip #1 error	0.03 mm	0.15 mm	-0.05 mm	0.06 mm	0.19 mm
Clip #2 error	-0.07 mm	0.11 mm	0.02 mm	-0.21 mm	-0.06 mm
Clip #3 error	-0.67 mm	-0.51 mm	-0.41 mm	-0.60 mm	-0.48 mm
Clip #4 error	-0.51 mm	-0.49 mm	-0.55 mm	-0.51 mm	-0.53 mm

Clip to surface distances					
	Series #1	Series #2	Series #3	Series #4	Series #5
Clip #1 - surface	-0.01 mm	0.03 mm	0.03 mm	-0.25 mm	-0.03 mm
Clip #2 - surface	0.01 mm	-0.02 mm	-0.02 mm	0.27 mm	0.05 mm
Clip #3 - surface	-0.01 mm	-0.04 mm	-0.04 mm	-0.38 mm	-0.06 mm
Clip #4 - surface	0.01 mm	0.04 mm	0.04 mm	0.32 mm	0.06 mm

Clip to limbus distances					
	Series #1	Series #2	Series #3	Series #4	Series #5
Clip #1 - limbus					Clinical




## In-house developed software for supporting treatment planning

- Tumor base entrance
- MRI registration
- Plan evaluation




## Development of Beam model


- Axial & lateral profiles
- Range
- Modulation
- Multiprofile algorithm
- Real time calculations



# 3D dose distribution in Eclipse Ocular Proton Planning





# Passive scattering beam formation devices




## ■ Range modulation – Spread Out Bragg Peak (SOBP)

- rotating wheel
- changing PMMA thickness



Varian Medical Systems, *Eclipse Ocular Proton Planning User Guide*, 2007


# Spread Out Bragg Peak formation




Modulator

# Experimental verification of modulators

using 3D water phantom scanner and Markus ionization chamber





It did not look like SOBP 😞






# Beam time structure of AIC–144 cyclotron

- Pulse repetition 50 [Hz]
- Pulse length 0.46 [ms]



# SOBP simulator software

- Beam parameters
- Modulator definition
- Measurement conditions



- Conclusion from measurements and SOBP simulations
  - problem is not a consequence of wrong measurement conditions
  - it depends on:
    - pulsed beam structure
    - modulator rotational speed
  - ... it is a sort of Wagon wheel effect.



# Equation for stroboscopic effect

## Methods

$$T_{modulator} = \frac{M}{n} \cdot T_{beam} \rightarrow T_{modulator} = \left( k + \frac{m}{n} \right) \cdot T_{beam}$$

where  $M, k, m, n$  are all integers and  $m < n$


$T_{beam}$

– beam pulse repetition time


$T_{modulator}$

– modulator wheel section recurrence time

## Results




# Experimental verification of calculations




Theoretical model has been confirmed experimentally

# Searching for optimal asynchronous modulator rotational frequency


$W_n(\alpha) = \{x_1, \dots, x_n\}$  for  $x_n = n\alpha \pmod{1}$   
where  $n = 1, 2, \dots$  and  $\alpha \in [0, 1)$



# FINAL RESULT – Perfect SOBP at 33.1 Hz




# Nature solves the equidistribution equation



Phyllotaxis of a plant  
equidistribution of sun light over leaves

Golden angle

$$\alpha = \tau = \frac{\sqrt{5} - 1}{2}$$



Rotational speed  
of modulator:

~ 32.725 Hz




## ■ Golden angle:

- Most uniform distribution of beam pulses (no recurrence)
- Very low dose discrepancy, but ...
  
- Mechanically unavailable frequency
- ~32.725 Hz is unfortunately very close to a high resonant frequency (32.8125 Hz) by less than 0.1 Hz




Golden Angle – 0.1°



Golden Angle



Golden Angle + 0.1°





## My name is A, QA – quality assurance



Centrum Onkologii  
Instytut im. Marii Skłodowskiej-Curie  
Oddział w Krakowie




Szpital  
Uniwersytecki  
w Krakowie



## In-house developed phantoms and scanners



PMMA range phantom



Lateral profile scanner




3D scanner and water phantom

# 2011.02.15 – Treatment of the first two patients





# In-house developed Patient Positioning Verification System



It allows for quick patient positioning with submillimeter precision

# Treatment delivery – 4 fractions, 15 Gy<sub>RBE</sub> each



Number of fraction	Dose delivered (planned) [CGE]	Dose delivered [CGE]	Independent dose controle [CGE]	Total dose [CGE]	Time [s]
Fraction 1	15.00	15.001	15.068	15.001	51
Fraction 2	15.00	15.044	15.057	30.045	53.5
Fraction 3	15.00	15.020	15.043	45.065	60.5
Fraction 4	15.00	15.026	15.026	60.091	63.5

## The team almost complete



prof. M. Jeżabek



Movie by dr hab. Jerzy Grębosz  
*Terapia protonowa nowotworów oka*  
[sekretariat.ccb@ifj.edu.pl](mailto:sekretariat.ccb@ifj.edu.pl)






- **292 patients** of University Hospital in Krakow treated:
  - 128 patients at AIC-144
  - 164 patients at CCB ELTR
- \*Age between 17 to 75 years
  - 52 years on average
  - 3% patients below < 22
- \*Female 46%, Male 54%
- \*Right eye 49%, left eye 51%
- \*Tumor height
  - < 5mm 72 %
  - 5-10mm 24 %
  - > 10mm 4%
- \*Follow up of 93% patients → **97% local control**

\*Romanowska-Dixon B, Markiewicz A, Sas-Korczyńska B, Medoń D, Walasek T. Evaluation of intraocular proton beam irradiation complications after choroidal melanoma treatment. Klinika Oczna / Acta Ophthalmologica Polonica. 2016;118(4):289-292.  
doi:10.5114/ko.2016.71741.


\*Romanowska-Dixon B Terapia protonowa czerniaka naczyniówka, Seminarium, 2016

# Detectors and dosimetry

- Two-dimensional dosimetry of radiotherapeutic proton beams using thermoluminescence foils, *Czopyk L, Kajdrowicz T, Kłosowski M, et al. (2007)*, *Radiation Protection Dosimetry* (2007), pp. 1–5
- Individual patient shielding for a proton eye therapy facility, *Cywicka-Jakiel T, Stolarczyk L, Swakoń J, et al.*, *Radiat. Meas.*, **45** (2010) 1127
- Evaluation of risk of secondary cancer occurrence after proton radiotherapy of ocular tumours, *Stolarczyk L, Horwacik T, et al.*, 2011, *Radiat. Meas.* 46, 1944-1947
- Alanine dosimetry of 60 MeV proton beam - preliminary results, *Michalec B, Mierzwińska G, Sowa U, et al. (2012)*, *Nukleonika*, 57, 503-506
- A monitoring system for the 60 MeV radiotherapy proton beam at IFJ PAN using a scintillating screen and a CCD camera, *Boberek et al. (2014)*, *Romanian Rep. Phys.* 66, 5–15
- Dosimetric characterization of collimators for spatially fractionated proton therapy of the eye, *Tobola-Galus A, Swakoń J, Olko P*, *Radiation Protection Dosimetry*, Volume 180, Issue 1-4, August 2018, Pages 351–354




- Metastasis inhibition after proton beam,  $\beta$ - and  $\gamma$ -irradiation of melanoma growing in the hamster eye, *Romanowska-Dixon B, Elas M, Swakoń J, et al.*, *Acta Biochimica Polonica*, 2013, Vol. 60, No 3/2013 307–311
- Relative biological effectiveness of the 60-MeV therapeutic proton beam at the Institute of Nuclear Physics (IFJ PAN) in Kraków, Poland, *Słonina D, Biesaga B, Swakoń J, et al.*, *Radiat Environ Biophys*. 2014 Nov;53(4):745-54
- Response of human lymphocytes to proton radiation of 60 MeV compared to 250 kV X-rays by the cytokinesis-block micronucleus assay, *J. Miszczyk J, Rawoń K, Panek A, et al.*, *Radiother Oncol.*, 115 (2015) 128-134
- Biological effects and inter-individual variability in peripheral blood lymphocytes of healthy donors exposed to 60 MeV proton radiotherapeutic beam, *Panek A, Miszczyk J, Swakoń J, Int. J. Radiat. Biol.*, 94 (2018) 1085-1094
- and more ...



**Figure 1.** Hamster eye irradiation with proton beam.

(A) Hamster in the animal positioning system, (B) hamster eye with the tumor, magnification 10x and (C) proton beam dose depth distribution and lateral profiles of the beam used for hamster eye irradiation.








**Fig. 1** Depth-dose distributions of the proton beam produced at the IFJ PAN Kraków (nominal energy 60 MeV) measured in a water phantom using a Marcus ion chamber. *Upper panel:* pristine beam; *lower panel:* SOBP. Arrows indicate positions at which cells (human fibroblasts) were irradiated: near (at 27.85 mm) the maximum of the Bragg peak in a pristine beam, and at three depths (2, 15, and 27 mm) of the SOBP of full width 28.4 mm


**Fig. 2** Depth distributions of dose-averaged LET ( $LET_d$ ) and of IQR of  $LET_d$  (shaded) of the proton beam produced at the IFJ PAN; simulated by Monte Carlo calculations. *Upper panel:* pristine beam; *lower panel:* SOBP. Calculated values of  $LET_d$  at irradiation positions are also shown


# Testing electronics and intercomparisons

- Testing of electronics for first Polish satellite LEM
- Testing of electronics for GSM basestation of the manned flight to Moon
- PTCOG OPTIC group intercomparison using mailed dosimetry
- and more ...



# The proton eye physics team (10 years compilation)





DCA Team after last patient irradiation on AIC-144

## IT Team



DCP Team during  
commissioning of Proteus C-235



In developing and executing the clinical part of this project, the team of IFJ PAN **physicists and engineers** closely collaborated with

**ophthalmologists, radiation oncologists, radiologists, medical physicists, radiation therapist and nurses** from the Department of Ophthalmology and Ophthalmic Oncology (Collegium Medicum of the Jagiellonian University) and with

**radiation oncologists** from the Centre of Oncology – Institute in Krakow (currently National Institute of Oncology in Krakow).

## Podziękowania dla

Obecnej i poprzednim Dyrekcji IFJ PAN

Kierownika Centrum Cyklotronowego Bronowice

Kolegów i Koleżanek z *Samodzielną Pracownią Radioterapii Protonowej*

Kolegów i Koleżanek z *Działu Cyklotronu AIC-144*

Kolegów i Koleżanek z *Centrum Cyklotronowego Bronowice*

Kolegów i Koleżanek z *Działu Cyklotronu Proteus*

Kolegów i Koleżanek z *Zakładu Badań Radiacyjnych i Radioterapii Protonowej*

Kolegów i Koleżanek z *Zakładu Fizyki Radiacyjnej i Dozimetrii*

Kolegów i Koleżanek z *Działu Budowy Aparatury i Infrastruktury Naukowej*

Kolegów i Koleżanek z *Zakładów Naukowych*

Kolegów i Koleżanek ze wszystkich *laboratoriów badawczych i pomiarowych*

Kolegów i Koleżanek ze wszystkich *działów administracyjnych i ekonomicznych*

Kolegów i Koleżanek ze wszystkich *działów technicznych i pomocniczych*

Pracowników *Szpitala Uniwersyteckiego w Krakowie*

Pracowników *Narodowego Instytutu Onkologii Oddział w Krakowie*

Członków *Narodowego Konsorcjum Radioterapii Hadronowej*

Przyjaciół i Sympatyków projektu